CA
MED icon

CastleArk Alternatives’s Medifast MED Stock Holding History

CastleArk Alternatives’s Portfolio MED Stock Details MED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-12,065
Closed -$2.32M – 176
2021
Q3 		$2.32M Buy
+12,065
New +$2.97M 0.09% 178

Other funds holding MED

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CastleArk Alternatives's MED Position: Q4 2021 in Review

CastleArk Alternatives sold out of Medifast (MED) in Q4 2021, closing a stake of 12,065 shares — an estimated $2.32M sold.

CastleArk Alternatives first reported a position in MED in Q3 2021 and held it in 1 quarter. The position peaked at $2.32M in Q3 2021. 297 funds tracked by Wall St. Rank hold MED as of Q4 2021.

  • CastleArk Alternatives reported no remaining Medifast position as of Q4 2021 after selling out during the quarter.
  • CastleArk Alternatives sold 12,065 Medifast shares in Q4 2021, an estimated $2.32M.
  • CastleArk Alternatives first reported a position in Medifast in Q3 2021 and held it in 1 quarter.
  • CastleArk Alternatives's Medifast position peaked at $2.32M in Q3 2021.
  • 297 funds tracked by Wall St. Rank held Medifast as of Q4 2021.

Based on CastleArk Alternatives's 13F filing for Q4 2021, filed 18 Feb 2022.